Search

Your search keyword '"Manni, R"' showing total 528 results
Start Over Author "Manni, R"
528 results on '"Manni, R"'

151. Social aspects of epilepsy in the adult in seven European countries

Author

Beghi, E., Cornaggia, C. M., Hauser, W. A., Loeber, J. N., Thorbecke, R., Sonnen, A. E. H., Severi, S., Zolo, P., Specchio, L. M., Specchio, N., Boati, E., Defanti, C. A., Pinto, P., Breviario, E., Pasolini, M. P., Antonini, L., Aguglia, U., Russo, C., Gambardella, A., Giubergia, S., Zagnoni, P., Mirco Cosottini, Zaccara, G., Trio, R., Pisani, F., Russo, M., Oteri, G., Cavestro, C. E., David, A., Tonini, C., Gianetti, S., Avanzini, G., Arienti, F., Bogliun, G., Fiordelli, E., Airoldi, L., Tartara, A., Manni, R., Castelnovo, G., Murelli, R., Galimberti, C. A., Zanotta, N., Di Viesti, P., Zarrelli, M., Apollo, F., Steuernagel, E., Wolf, P., Runge, U., Krom, M. C. T. F. M., Heijden, C., Griet, J., Diaz-Obregon, C., Utrero, E., Brown, S. W., Coyle, H., Lopes-Lima, J. M., Beleza, P., Ferreira, E., Talvik, T., Beilmann, A., Belousova, E., Nikanorowa, M., Ravnik, I. M., Levart, T., Zupancic, N., Gromov, S., Lipatova, L. V., and Mikhailov, V.

161. ILAE classification of epilepsies: Its applicability and practical value of different diagnostic categories

Author

Avanzini, G., Franceschetti, S., Binelli, S., Panzica, F., Granata, T., Canger, R., Maria Paola Canevini, Sgrò, V., Viani, F., Romeo, A., Viri, M., Guareschi Cazzullo, A., Lenti, C., Beghi, E., Bogliun, G., Montanini, R., Basso, P. F., Tartara, A., Manni, R., Galimberti, C. A., Zacchetti, O., Guarneri, M., Arisi, A., Mironi, F., Marchini, M., Cernibori, A., Costa, P., Defanti, C. A., Boati, E., Antonini, L., Guarneri, B., Menegatti, E., Tiberti, A., and Valseriati, D.

162. A prospective randomized study on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy: Interim evaluation | Studio prospettico randomizzato sull'impatto clinico del monitoraggio terapeutico dei farmaci antiepilettici in pazienti con epilessia di recente diagnosi: Valutazione ad interim

Author

Bottacchi, E., Carenini, E., Boati, E., Porazzi, D., Grampa, G., Guerrini, R., Ferrari, A., Belmonte, A., Coppola, G., Scarpello, R., Zagnoni, P. G., Luca, G., Zaccara, G., Borgheresi, A., Viani, F., Viri, M., Mutani, R., Naldi, P., Gianelli, M., Benetello, P. P., Tartara, A., Galimberti, C., Manni, R., Sartori, I., Murri, L., Galli, R., Gneri, C., Ruggeri, S., Bramante, L., Gobbi, G., Bertani, G., pini antonella, Benedetti, P., Brinciotti, M., Giannotti, F., Mazza, S., Vaccario, M. L., Moro, E., Monaco, F., Rocchi, R., Carapelli, S., Morgando, E., Cremo, R., Mattei, M., Moscato, D., Sacerdote, I., Gentile, S., Zola, Nobili, M., Vivalda, L., Leotta, D., Bongiovanni, L. G., Benedetti, M. D., and Nappo, A.

169. Dopamine transporter neuroimaging and clinical predictors for phenoconversion of idiopathic REM sleep behavior disorder to overt synucleinopathy: an international multicenter study

Author

Arnaldi, D., Chincarini, A., Hu, M., Sonka, K., Boeve, B., Miyamoto, T., Puligheddu, M., Cock, V. Cochen, Terzaghi, M., Plazzi, G., Tachibana, N., Morbeli, S., Rolinski, M., Dusek, P., Lowe, V., Miyamoto, M., MICHELA FIGORILLI, Verbizier, D., Bossert, I., Antelmi, E., Meli, R., Barber, T., Trnka, J., Miyagawa, T., Serra, A., Bauckneht, M., Bradley, K., Zogala, D., Mcgowan, D., Pizza, F., Lennon, J., Manni, R., and Nobili, F.

170. A prospective randomized study on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy: Interim evaluation,Studio prospettico randomizzato sull'impatto clinico del monitoraggio terapeutico dei farmaci antiepilettici in pazienti con epilessia di recente diagnosi: Valutazione ad interim

Author

Bottacchi, E., Carenini, E., Boati, E., Porazzi, D., Grampa, G., Guerrini, R., Anna Rita Ferrari, Belmonte, A., Coppola, G., Scarpello, R., Zagnoni, P. G., Luca, G., Zaccara, G., Borgheresi, A., Viani, F., Viri, M., Mutani, R., Naldi, P., Gianelli, M., Benetello, P. P., Tartara, A., Galimberti, C., Manni, R., Sartori, I., Murri, L., Galli, R., Gneri, C., Ruggeri, S., Bramante, L., Gobbi, G., Bertani, G., Pini, A., Benedetti, P., Brinciotti, M., Giannotti, F., Mazza, S., Vaccario, M. L., Moro, E., Monaco, F., Rocchi, R., Carapelli, S., Morgando, E., Cremo, R., Mattei, M., Moscato, D., Sacerdote, I., Gentile, S., Zola, Nobili, M., Vivalda, L., Leotta, D., Bongiovanni, L. G., Benedetti, M. D., and Nappo, A.

185. A clinical, EEG and CT study in 21 cases of chronic respiratory failure

Author

Manni, R., Tartara, A., Marchioni, E., Maurelli, M., Gozzoli, L., Cerveri, I., Zoia, M. C., and Bruschi, C.

Abstract

A clinical, EEG and CT study was carried out on 21 patients with chronic stable respiratory failure. The neurological disturbances and mental deterioration observed were of a mild degree, and no severe alterations were detected at EEG. CT showed cerebral atrophy, but the type and prevalence did not differ substantially between patients studied and normal sex- and age-matched control subjects. The data gave evidence that in chronic stable repiratory failure cerebral function is only slightly affected.

Published
1987
Full Text
View/download PDF

191. Sleep attacks in Parkinson's disease: a clinical and polysomnographic study.

Author

Pacchetti, C., Martignoni, E., Terzaghi, M., Zangaglia, R., Mancini, F., Nappi, G., and Manni, R.

Subjects
PARKINSON'S disease, DROWSINESS, SLEEP disorder diagnosis, SLEEP-wake cycle, DOPAMINE agonists
Abstract

The objective of the study was to evaluate daytime sleepiness, (the features of episodes of sudden sleep onset), i.e., so-called sleep attacks (S As), in three male Parkinson's disease (PD) patients (mean age 66 years) on chronic therapy with ropirinole or pramipexole. A structured clinical interview, the Epworth Sleepiness Scale, and continuous 24-h ambulatory polysomnography were used to assess the features of SAs occurring in the patients in their normal home environments. The polysomnographic patterns characterizing SAs (sleep occurring against a background of wakefulness, and not pre- ceded by a feeling of sleepiness or by other heralding symptoms) were analyzed. The results showed that SAs can be clearly documented through polysomnographic monitoring and really, but rarely, occur in PD. SAs seem to represent the extreme of the continuum of daytime sleepiness observed in PD patients. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

193. Non-convulsive status epilepticus and generalised tonic–clonic seizures persisting in old age in a patient with idiopathic generalised epilepsy: a long-term observation.

Author

Zambrelli, E., Terzaghi, M., Sinforiani, E., and Manni, R.

Subjects
EPILEPSY, SPASMS, BRAIN diseases, OLD age, PATIENTS
Abstract

Persisting non-convulsive status epilepticus in a man with idiopathic generalised epilepsy is reported. After a first generalised tonic/clonic seizure on awakening one day at the age of 20, the patient experienced rare nonconvulsive status epilepticus until the age of 73, when the frequency of the episodes increased, in spite of the initiation of treatment with antiepileptic drugs. No significant cognitive decline was documented when the patient was 83. The existence of such conditions in the context of idiopathic generalised epilepsy shows the problems of syndromic diagnosis and of age dependency of some epileptic phenomena over the course of life with potential bidirectional influences between epileptic manifestations and senile processes [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

195. Singularities of theta divisors and the geometry of A5.

Author

Farkas, G., Grushevsky, S., Manni, R. Salvati, and Verra, A.

Subjects
*DIVISOR theory, *MATHEMATICAL singularities, *ABELIAN varieties, *JACOBIAN matrices, *DIMENSION theory (Algebra)
Abstract

We study the codimension two locus H in Ag consisting of principally polarized abelian varieties whose theta divisor has a singularity that is not an ordinary double point. We compute the class |H| CH².Ag/for every g. For g = 4, this turns out to be the locus of Jacobians with a vanishing theta-null. For g = 5, via the Prym map we show that H ⊂ A5 has two components, both unirational, which we describe completely. We then determine the slope of the effective cone of A5 and show that the component N0 of the Andreotti-Mayer divisor has minimal slope and the Iitaka dimension k(A5;N0 is equal to zero. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

197. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

Author

Postuma, Ronald, Iranzo, Alex, Hu, Michele, Högl, Birgit, Boeve, Bradley, Manni, Raffaele, Oertel, Wolfgang, Arnulf, Isabelle, Ferini-Strambi, Luigi, Puligheddu, Monica, Antelmi, Elena, Cochen De Cock, Valérie, Arnaldi, Dario, Mollenhauer, Brit, Videnovic, Aleksandar, Sonka, Karel, Jung, Ki-Young, Kunz, Dieter, Dauvilliers, Yves, Provini, Federica, Lewis, Simon, Buskova, Jitka, Pavlova, Milena, Heidbreder, Anna, Montplaisir, Jacques, Santamaria, Joan, Barber, Thomas, Stefani, Ambra, St Louis, Erik, Terzaghi, Michele, Janzen, Annette, Leu-Semenescu, Smandra, Plazzi, Guiseppe, Nobili, Flavio, Sixel-Doering, Friederike, Dusek, Petr, Bes, Frederik, Cortelli, Pietro, Ehgoetz Martens, Kaylena, Gagnon, Jean-François, Gaig, Carles, Zucconi, Marco, Trenkwalder, Claudia, Gan-Or, Ziv, Lo, Christine, Rolinski, Michal, Mahlknecht, Philip, Holzknecht, Evi, Boeve, Angel, Teigen, Luke, Toscano, Gianpaolo, Mayer, Geert, Morbelli, Silvia, Dawson, Benjamin, Pelletier, Amélie, St.Louis, Erik, Postuma, R. B., Iranzo, A., Hu, M., Hogl, B., Boeve, B. F., Manni, R., Oertel, W. H., Arnulf, I., Ferini-Strambi, L., Puligheddu, M., Antelmi, E., Cochen De Cock, V., Arnaldi, D., Mollenhauer, B., Videnovic, A., Sonka, K., Jung, K. -Y., Kunz, D., Dauvilliers, Y., Provini, F., Lewis, S. J., Buskova, J., Pavlova, M., Heidbreder, A., Montplaisir, J. Y., Santamaria, J., Barber, T. R., Stefani, A., Louis, S. E. K., Terzaghi, M., Janzen, A., Leu-Semenescu, S., Plazzi, G., Nobili, F., Sixel-Doering, F., Dusek, P., Bes, F., Cortelli, P., Ehgoetz Martens, K., Gagnon, J. -F., Gaig, C., Zucconi, M., Trenkwalder, C., Gan-Or, Z., Lo, C., Rolinski, M., Mahlknecht, P., Holzknecht, E., Boeve, A. R., Teigen, L. N., Toscano, G., Mayer, G., Morbelli, S., Dawson, B., Pelletier, A., Postuma R.B., Iranzo A., Hu M., Hogl B., Boeve B.F., Manni R., Oertel W.H., Arnulf I., Ferini-Strambi L., Puligheddu M., Antelmi E., Cochen De Cock V., Arnaldi D., Mollenhauer B., Videnovic A., Sonka K., Jung K.-Y., Kunz D., Dauvilliers Y., Provini F., Lewis S.J., Buskova J., Pavlova M., Heidbreder A., Montplaisir J.Y., Santamaria J., Barber T.R., Stefani A., Louis S.E.K., Terzaghi M., Janzen A., Leu-Semenescu S., Plazzi G., Nobili F., Sixel-Doering F., Dusek P., Bes F., Cortelli P., Ehgoetz Martens K., Gagnon J.-F., Gaig C., Zucconi M., Trenkwalder C., Gan-Or Z., Lo C., Rolinski M., Mahlknecht P., Holzknecht E., Boeve A.R., Teigen L.N., Toscano G., Mayer G., Morbelli S., Dawson B., Pelletier A., McGill University = Université McGill [Montréal, Canada], Innsbruck Medical University [Austria] (IMU), Mayo Clinic [Rochester], Philipps University of Marburg, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), University of Bologna, Euromov (EuroMov), Université de Montpellier (UM), University of Genoa (UNIGE), University Medical Center Göttingen (UMG), First Faculty of Medicine Charles University [Prague], Seoul National University Hospital, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University of Münster, Hôpital du Sacré-Coeur de Montréal, University of Oxford [Oxford], Ospedale Bellaria [Bologna, Italy], and Université du Québec à Montréal = University of Québec in Montréal (UQAM)

Subjects
0301 basic medicine, Male, Parkinson's disease, multiple system atrophy, dementia with Lewy bodies, REM sleep behaviour disorder, Kaplan-Meier Estimate, REM Sleep Behavior Disorder, Cohort Studies, 0302 clinical medicine, Risk Factors, Restless legs syndrome, Prospective Studies, Depression (differential diagnoses), Parkinsonism, Hazard ratio, Parkinson Disease, Middle Aged, Prognosis, humanities, 3. Good health, Disease Progression, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Female, Parkinson’s disease, Lewy Body Disease, medicine.medical_specialty, Polysomnography, Prodromal Symptoms, Parkinson’s disease, REM sleep behaviour disorder, dementia with Lewy bodies, multiple system atrophy, REM sleep behavior disorder, 03 medical and health sciences, Parkinsonian Disorders, Internal medicine, dementia with Lewy bodie, mental disorders, medicine, Dementia, Humans, Aged, Proportional Hazards Models, business.industry, Dementia with Lewy bodies, Scientific Commentaries, medicine.disease, 030104 developmental biology, Neurology (clinical), business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, 030217 neurology & neurosurgery, Forecasting
Abstract

International audience; Idiopathic REM sleep behaviour disorder (iRBD) is a powerful early sign of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. This provides an unprecedented opportunity to directly observe prodromal neurodegenerative states, and potentially intervene with neuroprotective therapy. For future neuroprotective trials, it is essential to accurately estimate phenoconversion rate and identify potential predictors of phenoconversion. This study assessed the neurodegenerative disease risk and predictors of neurodegeneration in a large multicentre cohort of iRBD. We combined prospective follow-up data from 24 centres of the International RBD Study Group. At baseline, patients with polysomnographically-confirmed iRBD without parkinsonism or dementia underwent sleep, motor, cognitive, autonomic and special sensory testing. Patients were then prospectively followed, during which risk of dementia and parkinsonsim were assessed. The risk of dementia and parkinsonism was estimated with Kaplan-Meier analysis. Predictors of phenoconversion were assessed with Cox proportional hazards analysis, adjusting for age, sex, and centre. Sample size estimates for disease-modifying trials were calculated using a time-to-event analysis. Overall, 1280 patients were recruited. The average age was 66.3 ± 8.4 and 82.5% were male. Average follow-up was 4.6 years (range = 1-19 years). The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up. The rate of phenoconversion was significantly increased with abnormal quantitative motor testing [hazard ratio (HR) = 3.16], objective motor examination (HR = 3.03), olfactory deficit (HR = 2.62), mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2.11), an abnormal DAT scan (HR = 1.98), colour vision abnormalities (HR = 1.69), constipation (HR = 1.67), REM atonia loss (HR = 1.54), and age (HR = 1.54). There was no significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunction, orthostatic symptoms, depression, anxiety, or hyperechogenicity on substantia nigra ultrasound. Among predictive markers, only cognitive variables were different at baseline between those converting to primary dementia versus parkinsonism. Sample size estimates for definitive neuroprotective trials ranged from 142 to 366 patients per arm. This large multicentre study documents the high phenoconversion rate from iRBD to an overt neurodegenerative syndrome. Our findings provide estimates of the relative predictive value of prodromal markers, which can be used to stratify patients for neuroprotective trials.

Published
2019
Full Text
View/download PDF

198. Anodal transcranial direct current stimulation in chronic migraine and medication overuse headache: A pilot double-blind randomized sham-controlled trial.

Author

De Icco, R., Putortì, A., De Paoli, I., Ferrara, E., Cremascoli, R., Terzaghi, M., Toscano, G., Allena, M., Martinelli, D., Cosentino, G., Grillo, V., Colagiorgio, P., Versino, M., Manni, R., Sances, G., Sandrini, G., and Tassorelli, C.

Subjects
*TRANSCRANIAL direct current stimulation, *MIGRAINE, *ALPHA rhythm, *MEDICATION overuse headache, *DRUGS, *THALAMOCORTICAL system
Abstract

• The study aims to assess the role tDCS as add-on to detoxification in chronic migraine associated to medication overuse headache. • Anodal tDCS was superior to sham stimulation in reducing monthly migraine days after 1 month and 6 months from detoxification. • Alpha rhythm was significantly enhanced over occipital leads in the tDCS group when compared to the sham group. Little evidence is available on the role of transcranial direct current stimulation (tDCS) in patients affected by chronic migraine (CM) and medication overuse headache (MOH). We aim to investigate the effects of tDCS in patients with CM and MOH as well as its role on brain activity. Twenty patients with CM and MOH were hospitalized for a 7-day detoxification treatment. Upon admission, patients were randomly assigned to anodal tDCS or sham stimulation delivered over the primary motor cortex contralateral to the prevalent migraine pain side every day for 5 days. Clinical data were recorded at baseline (T0), after 1 month (T2) and 6 months (T3). EEG recording was performed at T0, at the end of the tDCS/Sham treatment, and at T2. At T2 and T3, we found a significant reduction in monthly migraine days (p = 0.001), which were more pronounced in the tDCS group when compared to the sham group (p = 0.016). At T2, we found a significant increase of alpha rhythm in occipital leads, which was significantly higher in tDCS group when compared to sham group. tDCS showed adjuvant effects to detoxification in the management of patients with CM and MOH. The EEG recording showed a significant potentiation of alpha rhythm, which may represent a correlate of the underlying changes in cortico-thalamic connections. This study suggests a possible role for tDCS in the treatment of CM and MOH. The observed clinical improvement is coupled with a potentiation of EEG alpha rhythm. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

199. Standard procedures for the diagnostic pathway of sleep‐related epilepsies and comorbid sleep disorders: an EAN, ESRS and ILAE‐Europe consensus review.

Author

Nobili, L., Weerd, A., Rubboli, G., Beniczky, S., Derry, C., Eriksson, S., Halasz, P., Högl, B., Santamaria, J., Khatami, R., Ryvlin, P., Rémi, J., Tinuper, P., Bassetti, C., Manni, R., Koutroumanidis, M., and Vignatelli, L.

Subjects
*SLEEP disorders, *COMORBIDITY, *SEIZURES (Medicine), *SOMNOLOGY, *RESTLESS legs syndrome
Abstract

Background and purpose: Some epilepsy syndromes (sleep‐related epilepsies, SREs) have a strong link with sleep. Comorbid sleep disorders are common in patients with SRE and can exert a negative impact on seizure control and quality of life. Our purpose was to define the standard procedures for the diagnostic pathway of patients with possible SRE (scenario 1) and the general management of patients with SRE and comorbidity with sleep disorders (scenario 2). Methods: The project was conducted under the auspices of the European Academy of Neurology, the European Sleep Research Society and the International League Against Epilepsy Europe. The framework entailed the following phases: conception of the clinical scenarios; literature review; statements regarding the standard procedures. For the literature search a stepwise approach starting from systematic reviews to primary studies was applied. Published studies were identified from the National Library of Medicine's MEDLINE database and Cochrane Library. Results: Scenario 1: Despite a low quality of evidence, recommendations on anamnestic evaluation and tools for capturing the event at home or in the laboratory are provided for specific SREs. Scenario 2: Early diagnosis and treatment of sleep disorders (especially respiratory disorders) in patients with SRE are likely to be beneficial for seizure control. Conclusions: Definitive procedures for evaluating patients with SRE are lacking. Advice is provided that could be of help for standardizing and improving the diagnostic approach of specific SREs. The importance of identifying and treating specific sleep disorders for the management and outcome of patients with SRE is underlined. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

200. Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis.

Author

Capittini, C., De Silvestri, A., Terzaghi, M., Scotti, V., Rebuffi, C., Pasi, A., Manni, R., Martinetti, M., and Tinelli, C.

Subjects
*HLA histocompatibility antigens, *NARCOLEPSY, *CATAPLEXY, *GENETIC testing, *META-analysis, *BLACK people, *DISEASE susceptibility, *NATIVE Americans, *WHITE people, *HLA-B27 antigen
Abstract

Study Objectives: we performed a meta-analysis to assess the usefulness of HLA testing for Narcolepsy diagnosis in four major ethnical groups: Asians, Afro-Americans, Amerindians and Caucasians.Methods: PubMed, EMBASE, Web of Science, Scopus and Cochrane databases were searched for articles in English and French published before October 2017 on HLA class II alleles in Narcolepsy. We included case-control studies, cross-sectional and retrospective cohort studies with patients diagnosed following the International classifications of sleep disorders (1990-2012) and ethnically matched controls. Following PRISMA guidelines, two investigators independently extracted data according to the inclusion criteria listed in PROSPERO CRD42017058677. A third researcher was consulted for discrepancies. We extracted and pooled adjusted OR using random-effect models. We verified the strength of the association between HLA-DQB1*06:02 and the worldwide distribution of Narcolepsy type 1 (NT1) and type 2 (NT2); furthermore, we pooled the OR measuring the association between HLA-DQB1*06:02 and NT1, NT2 and hypersomniacs.Results: We identified 511 titles. Of these, 12 case-control studies were included, for a total of 2077 NT1 patients, 235 NT2 patients, 161 hypersomniacs and 7802 controls. In the population-stratified analysis, HLA-DQB1*06:02 conferred an increased risk for NT1 (OR: 24.1, IC: 14.6-39.5, p < 0.001) and NT2 (OR: 3.9; IC: 2.2-6.8, p < 0.001). For NT1 the pooled estimated positive Likelihood Ratio (LR+) was 5.94 (IC: 3.71-9.51) and the negative Likelihood Ratio (LR-) was 0.23 (IC: 0.16-0.33); for NT2 LR+ was 3.35 (IC: 2.08-5.38) and LR- 0.72 (IC: 0.63-0.81). Moreover, for hypersomniacs LR+ was 1.436 (IC 0.668-3.089) and LR- 0.903 (IC 0.714-1.142).Conclusions: Our data support the preponderant role of HLA-DQB1*06:02 in susceptibility to NT1/NT2 across all ethnicities. HLA-DQB1*06:02 negativity should make clinicians cautious in excluding other diagnoses. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results